Eli Lilly’s revenue composition over the last five years tells a powerful story of strategic portfolio evolution. Between 2020 and 2024, the company transitioned from a diabetes-heavy mix toward a growth engine dominated by GLP-1 therapies and oncology assets, driving a sharp rise in top-product revenues.
Annual Revenue Growth from Top 10 Products
-
2020: $24.54B
-
2021: $28.32B
-
2022: $28.54B
-
2023: $34.12B
-
2024: $45.04B
This nearly 84% growth in just four years highlights Lilly’s success in scaling blockbuster therapies while gradually reducing reliance on older insulin brands.
2020: A Diabetes-Centric Portfolio
In 2020, Lilly’s top products were led by:
-
Trulicity ($5.07B)
-
Humalog ($2.63B)
-
Alimta ($2.33B)
-
Taltz, Jardiance, and Basaglar
The portfolio leaned heavily toward diabetes and insulin therapies, with oncology and immunology playing secondary roles.
2021–2022: Expansion Without Acceleration
By 2021 and 2022, total revenue from top products stabilized around $28.3–$28.5B:
-
Trulicity crossed $7B
-
Verzenio and Taltz gained momentum
-
COVID-19 antibodies briefly appeared in 2022
This phase marked portfolio broadening, but not yet explosive growth.
2023: The Inflection Point
In 2023, top-product revenue jumped to $34.12B, driven by:
-
Trulicity ($7.13B)
-
Mounjaro ($5.16B)
-
Verzenio ($3.86B)
-
Taltz ($2.76B)
This year clearly signaled Lilly’s pivot toward next-generation metabolic therapies, with Mounjaro emerging as a high-impact asset.
2024: The GLP-1 Era Takes Over
2024 represents a structural shift in Lilly’s business:
-
Mounjaro: $11.54B
-
Verzenio: $5.31B
-
Trulicity: $5.25B
-
Zepbound: $4.93B
-
Jardiance & Taltz: ~$3B+ each
With $45.04B generated by the top 10 products alone, GLP-1 and obesity therapies became the core growth drivers, while legacy insulin brands like Humulin and Humalog now contribute a smaller share.
Key Takeaways
🔹 Blockbuster concentration increased, led by Mounjaro and Verzenio
🔹 Diabetes care evolved from insulin to GLP-1–based innovation
🔹 Oncology and immunology remain strong secondary pillars
🔹 Lilly’s portfolio is now future-oriented, high-growth, and scalable
Bottom Line
Eli Lilly’s top-10 product mix from 2020 to 2024 reflects one of the most successful portfolio transformations in Big Pharma—moving decisively from mature therapies to next-decade growth platforms in obesity, diabetes, and oncology.